(via TheNewswire)
![](https://tnw-c.thenewswire.com/data/tnw/clients/logos/Av7F880Y.png)
![](https://tnw-c.thenewswire.com/data/tnw/img/facebook.png)
![](https://tnw-c.thenewswire.com/data/tnw/img/twitter.png)
![](https://tnw-c.thenewswire.com/data/tnw/img/linkedIn.png)
Dr. Siewerdsenis a Professor and Vice-Chair in the
Dr. Siewerdsen’s contributions include the development of new 3D imaging systems for image-guided radiation therapy, image-guided surgery, and point-of-care diagnostic imaging in orthopaedics and neuro-critical care. He was on the team that first introduced CBCT for guidance of radiotherapy – a technology that is now a standard-of-care. His work on CBCT mobile C-arms has helped to introduce intraoperative CBCT and high-precision guidance in numerous surgical applications. He also developed some of the first CBCT systems for orthopaedic extremity imaging as well as high-quality point-of-care imaging of head trauma. Underlying such systems are advanced algorithms for high-quality 3D image reconstruction and registration as well as mathematical models of 3D image quality to optimize the design of new imaging systems for particular imaging tasks. Dr. Siewerdsen’s work is marked by close clinical collaboration with radiologists, surgeons, and radiation oncologists to accelerate the translation of concepts to first clinical applications.
Dr. Siewerdsen’s appointment to the
The Company has granted Dr. Siewerdsen 100,000 stock options at an exercise price of
The stock options are in effect for two (2) years and vest immediately.
ON BEHALF OF THE BOARD
Chief Executive Officer
Contact Information
For investor relations inquiries contact:
Phone: 1-778-962-0234
Email:IR@izocorp.com
For general inquiries contact:
Phone: 1-833-IZOCORP
Email:info@izocorp.com
About
The initial indication for use for breast CT as a diagnostic device has been confirmed. Forthcoming business objectives include identifying additional indications for use, development of accessories, and additional products, all aimed at making breast CT an indispensable tool for improving the outcomes of breast cancer.
Additional information about
Forward Looking Statements
This document may contain forward-looking statements that are based on the Company's expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Copyright (c) 2021 TheNewswire - All rights reserved.
Copyright (c) 2021 TheNewswire - All rights reserved., source